This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barth, R. F. Articles by Soloway, A. H. Search for Related Content PubMed PubMed Citation Articles by Barth, R. F. Articles by Soloway, A. H.

Boron Neutron Capture Therapy of Brain Tumors: Enhanced Survival following Intracarotid Injection of either Sodium Borocaptate or Boronophenylalanine with or without Blood-Brain Barrier Disruption¹

Department of Pathology [R. F. B., W. Y., J. H. R.], Division of Epidemiology and Biometrics/School of Public Health [M. L. M.], Division of Neurosurgery [J. H. G.], and College of Pharmacy [A. H. S.], The Ohio State University, Columbus, Ohio 43210, and Medical Department, Brookhaven National Laboratory, Upton, New York 11973 [D. D. J., M. M. N.]

The purpose of the present study was to determine whether the efficacy of boron neutron capture therapy could be enhanced by means of intracarotid (i.c.) injection of sodium borocaptate (BSH) or boronophenylalanine (BPA) with or without blood-brain barrier disruption (BBB-D). For biodistribution studies, F98 glioma-bearing rats were injected i.v. or i.c. with either BSH (30 mg of boron/kg of body weight) or BPA (24 mg of boron/kg of body weight) with or without mannitol-induced, hyperosmotic BBB-D and killed 2.5 h later. The highest tumor boron concentrations for BSH and BPA were attained following i.c. injection with BBB-D (48.6 and 94.0 µg/g, respectively) compared to i.c. (30.8 and 42.7 µg/g) and i.v. injection (12.9 and 20.8 µg). Using the same doses of BSH and BPA, therapy experiments were initiated 14 days after intracerebral implantation of F98 glioma cells. Animals were irradiated 2.5 h after i.v. or i.c. administration of the capture agent with or without BBB-D using a collimated beam of thermal neutrons at the Brookhaven Medical Research Reactor. The median survival times of rats given BSH or BPA i.c. were 52 and 69 days, respectively, for rats with BBB-D; 39 and 48 days for rats without BBB-D; 33 and 37 days for i.v. injected rats; 29 days for irradiated controls; and 24 days for untreated controls. i.c. injection of either BSH or BPA resulted in highly significant enhancement (P = 0.01 and P = 0.0002, respectively) of survival times compared to i.v. injection, and this was further augmented by BBB-D (P = 0.02 and P = 0.04, respectively) compared to i.c. injection. Normal brain tissue tolerance studies were carried out with non-tumor-bearing rats, which were treated in the same way as tumor-bearing animals. One year after irradiation, the brains of these animals showed only minimal radiation-induced changes in the choroid plexus, but no differences were discernible between irradiated controls and those that had BBB-D followed by i.c. injection of either BSH or BPA. Our data clearly show that the route of administration, as well as BBB-D, can enhance the uptake of BSH and BPA, and, subsequently, the efficacy of boron neutron capture therapy.

¹ This work was supported by United States Department of Energy Grant DE-AC02-76CH000016. Presented in part at the 44th Annual Meeting of the Radiation Research Society, Chicago, Illinois, April 14–17, 1996, and the Seventh International Symposium on Neutron Capture Therapy, Zürich, Switzerland, September 4–7, 1996.

² To whom requests for reprints should be addressed, at The Ohio State University, Department of Pathology, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210.

Received 9/ 3/96. Accepted 1/16/97.

This article has been cited by other articles:

				W. Yang, G. Wu, R. F. Barth, M. R. Swindall, A. K. Bandyopadhyaya, W. Tjarks, K. Tordoff, M. Moeschberger, T. J. Sferra, P. J. Binns, et al. Molecular Targeting and Treatment of Composite EGFR and EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibodies Clin. Cancer Res., February 1, 2008; 14(3): 883 - 891. [Abstract] [Full Text] [PDF]

				T. L. Nichols, L. F. Miller, G. W. Kabalka, and T. M. Dudney Microdosimetric study for interpretation of outcomes from boron neutron capture therapy clinical trials Radiat Prot Dosimetry, August 1, 2007; 126(1-4): 645 - 647. [Abstract] [Full Text] [PDF]

				G. Wu, W. Yang, R. F. Barth, S. Kawabata, M. Swindall, A. K. Bandyopadhyaya, W. Tjarks, B. Khorsandi, T. E. Blue, A. K. Ferketich, et al. Molecular Targeting and Treatment of an Epidermal Growth Factor Receptor-Positive Glioma Using Boronated Cetuximab Clin. Cancer Res., February 15, 2007; 13(4): 1260 - 1268. [Abstract] [Full Text] [PDF]

				W. Yang, R. F. Barth, G. Wu, S. Kawabata, T. J. Sferra, A. K. Bandyopadhyaya, W. Tjarks, A. K. Ferketich, M. L. Moeschberger, P. J. Binns, et al. Molecular Targeting and Treatment of EGFRvIII-Positive Gliomas Using Boronated Monoclonal Antibody L8A4. Clin. Cancer Res., June 15, 2006; 12(12): 3792 - 3802. [Abstract] [Full Text] [PDF]

				C.-H. Hsieh, Y.-F. Chen, F.-D. Chen, J.-J. Hwang, J.-C. Chen, R.-S. Liu, J.-J. Kai, C.-W. Chang, and H.-E. Wang Evaluation of Pharmacokinetics of 4-Borono-2-18F-Fluoro-L-Phenylalanine for Boron Neutron Capture Therapy in a Glioma-Bearing Rat Model with Hyperosmolar Blood-Brain Barrier Disruption J. Nucl. Med., November 1, 2005; 46(11): 1858 - 1865. [Abstract] [Full Text] [PDF]

				R. F. Barth, J. A. Coderre, M. G. H. Vicente, and T. E. Blue Boron Neutron Capture Therapy of Cancer: Current Status and Future Prospects Clin. Cancer Res., June 1, 2005; 11(11): 3987 - 4002. [Abstract] [Full Text] [PDF]

				R. F. Barth, W. Yang, A. S. Al-Madhoun, J. Johnsamuel, Y. Byun, S. Chandra, D. R. Smith, W. Tjarks, and S. Eriksson Boron-Containing Nucleosides as Potential Delivery Agents for Neutron Capture Therapy of Brain Tumors Cancer Res., September 1, 2004; 64(17): 6287 - 6295. [Abstract] [Full Text] [PDF]

				W. Yang, R. F. Barth, D. M. Adams, M. J. Ciesielski, R. A. Fenstermaker, S. Shukla, W. Tjarks, and M. A. Caligiuri Convection-enhanced Delivery of Boronated Epidermal Growth Factor for Molecular Targeting of EGF Receptor-positive Gliomas Cancer Res., November 15, 2002; 62(22): 6552 - 6558. [Abstract] [Full Text] [PDF]

				Rolf. F. Barth, W. Yang, D. M. Adams, J. H. Rotaru, S. Shukla, M. Sekido, W. Tjarks, R. A. Fenstermaker, M. Ciesielski, M. M. Nawrocky, et al. Molecular Targeting of the Epidermal Growth Factor Receptor for Neutron Capture Therapy of Gliomas Cancer Res., June 1, 2002; 62(11): 3159 - 3166. [Abstract] [Full Text] [PDF]

				S. Samnick, J. B. Bader, D. Hellwig, J. R. Moringlane, C. Alexander, B. F.M. Romeike, W. Feiden, and C.-M. Kirsch Clinical Value of Iodine-123-Alpha-Methyl-L-Tyrosine Single-Photon Emission Tomography in the Differential Diagnosis of Recurrent Brain Tumor in Patients Pretreated for Glioma at Follow-Up J. Clin. Oncol., January 15, 2002; 20(2): 396 - 404. [Abstract] [Full Text] [PDF]

				E. L. Kreimann, M. E. Itoiz, A. Dagrosa, R. Garavaglia, S. Farias, D. Batistoni, and A. E. Schwint The Hamster Cheek Pouch as a Model of Oral Cancer for Boron Neutron Capture Therapy Studies: Selective Delivery of Boron by Boronophenylalanine Cancer Res., December 1, 2001; 61(24): 8775 - 8781. [Abstract] [Full Text] [PDF]

				D. R. Smith, S. Chandra, R. F. Barth, W. Yang, D. D. Joel, and J. A. Coderre Quantitative Imaging and Microlocalization of Boron-10 in Brain Tumors and Infiltrating Tumor Cells by SIMS Ion Microscopy: Relevance to Neutron Capture Therapy Cancer Res., November 1, 2001; 61(22): 8179 - 8187. [Abstract] [Full Text] [PDF]

				L. G. Remsen, M. A. Pagel, C. I. McCormick, S. A. Fiamengo, G. Sexton, and E. A. Neuwelt The Influence of Anesthetic Choice, PaCO2, and Other Factors on Osmotic Blood-Brain Barrier Disruption in Rats with Brain Tumor Xenografts Anesth. Analg., March 1, 1999; 88(3): 559 - 559. [Abstract] [Full Text] [PDF]